SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test.
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test.
复制标题
DOI:
10.3390/life12122064
复制
发表时间:
2022-12-09
期刊:
影响因子:
3.2
通讯作者:
Gozlan, Joel
中科院分区:
文献类型:
--
作者:
Marot, Stephane;Fofana, Djeneba Bocar;Flandre, Philippe;Malet, Isabelle;Zafilaza, Karen;Leducq, Valentin;Vivien, Diane;Mrabet, Sarah;Poignon, Corentin;Calvez, Vincent;Morand-Joubert, Laurence;Marcelin, Anne-Genevieve;Gozlan, Joel
The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale.
登录
查看更多内容
影响因子:
82.9
作者:
Lucas C;Klein J;Sundaram ME;Liu F;Wong P;Silva J;Mao T;Oh JE;Mohanty S;Huang J;Tokuyama M;Lu P;Venkataraman A;Park A;Israelow B;Vogels CBF;Muenker MC;Chang CH;Casanovas-Massana A;Moore AJ;Zell J;Fournier JB;Yale IMPACT Research Team;Wyllie AL;Campbell M;Lee AI;Chun HJ;Grubaugh ND;Schulz WL;Farhadian S;Dela Cruz C;Ring AM;Shaw AC;Wisnewski AV;Yildirim I;Ko AI;Omer SB;Iwasaki A
通讯作者:
Iwasaki A
DOI:
10.1016/j.jcv.2021.105024
发表时间:
2021-12
期刊:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
影响因子:
--
作者:
Lake DF;Roeder AJ;Kaleta E;Jasbi P;Pfeffer K;Koelbela C;Periasamy S;Kuzmina N;Bukreyev A;Grys TE;Wu L;Mills JR;McAulay K;Gonzalez-Moa M;Seit-Nebi A;Svarovsky S
通讯作者:
Svarovsky S
影响因子:
8.8
作者:
Hirabidian, Mickael;Bocket, Laurence;Demaret, Julie;Vuotto, Fanny;Rabat, Anthony;Faure, Karine;Labalette, Myriam;Hober, Didier;Lefevre, Guillaume;Alidjinou, Enagnon Kazali
通讯作者:
Alidjinou, Enagnon Kazali
DOI:
10.1056/nejmoa2109072
发表时间:
2021-10-14
期刊:
The New England journal of medicine
影响因子:
--
作者:
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者:
Regev-Yochay G
影响因子:
11.8
作者:
Marot, Stephane;Malet, Isabelle;Jary, Aude
通讯作者:
Jary, Aude